Intra Cellular Therapies reported $0 in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
ALKERMES ALKS:US USD 293.9M 633K
Aptinyx Inc APTX:US USD 24.71M 211K
Biocryst Pharmaceuticals BCRX:US USD 713.65M 91.47M
Biogen BIIB:US USD 6.28B 998M
Bristol Myers Squibb BMY:US USD 39.32B 222M
Cytokinetics CYTK:US USD 610.73M 411.31M
Esperion Therapeutics ESPR:US USD 259.49M 407K
Halozyme Therapeutics HALO:US USD 1.5B 258.29M
JAZZ PHA JAZZ:US USD 5.73B 294.18M
Marinus Pharmaceuticals MRNS:US USD 70.78M 430K
Neurocrine Biosciences NBIX:US USD 169.2M 200K
Novartis NVS:US USD 27.91B 530M
Supernus Pharmaceuticals SUPN:US USD 401.44M 529K
United Therapeutics UTHR:US USD 800M 0